Department of pediatrics, Mazandaran University of Medical Sciences, Sari Iran.
Pediatric infectious diseases research center, communicable Diseases institute, Mazandaran University of Medical Sciences, Sari Iran.
Ethiop J Health Sci. 2023 Jul;33(4):611-620. doi: 10.4314/ejhs.v33i4.7.
Enuresis, defined as involuntary nocturnal urination without any underlying organic disorder in a child expected to control urination, poses a common problem. This study evaluated the effectiveness of Tolterodine and Oxybutynin in children presenting with primary desmopressin-resistant enuresis.
A randomized clinical trial was undertaken involving 68 participants aged between 5 and 16 years, all suffering from primary enuresis. These patients were randomly assigned to one of two treatment groups for a three-month period: Group 1, treated with Oxybutynin and Desmopressin, and Group 2, treated with Tolterodine and Desmopressin. Data on demographics, clinical and laboratory findings, and subjective responses to treatment were gathered. The response was measured based on the frequency of wetting incidents per night and week and compared with pre-treatment data.
Patients were divided into two groups (30 patients in Group 1 and 38 patients in Group 2). The mean age of the patients was 88.97±27.09 months. In the first treatment group, 6 out of 30 patients (20%) experienced a complete treatment response, as did 5 out of 38 patients (13.2%) in the second treatment group. This difference between the groups was not statistically significant. Seven patients (23%) in the Oxybutynin group and 13 patients (34%) in the Tolterodine group reported a lack of response to treatment, a difference that also lacked statistical significance.
For patients resistant to Desmopressin, the addition of anticholinergic drugs elicited a significant response in over half of the patients. However, no benefit was observed in using either Oxybutynin or Tolterodine in the treatment of Desmopressin-resistant enuresis.
遗尿症是指儿童在预期能够控制排尿的情况下,出现无潜在器质性疾病的夜间无意识排尿,是一种常见问题。本研究评估了托特罗定和奥昔布宁在原发性去氨加压素抵抗性遗尿症患儿中的疗效。
进行了一项随机临床试验,纳入了 68 名年龄在 5 至 16 岁之间的原发性遗尿症患者。这些患者随机分为两组,分别接受为期三个月的治疗:第 1 组接受奥昔布宁和去氨加压素治疗,第 2 组接受托特罗定和去氨加压素治疗。收集了人口统计学、临床和实验室检查以及对治疗的主观反应数据。根据夜间和每周的湿衣次数来衡量反应,并与治疗前的数据进行比较。
患者分为两组(第 1 组 30 例,第 2 组 38 例)。患者的平均年龄为 88.97±27.09 个月。在第 1 组治疗中,30 例患者中有 6 例(20%)完全治疗反应,第 2 组治疗中 38 例患者中有 5 例(13.2%)完全治疗反应。两组之间的差异无统计学意义。奥昔布宁组有 7 例(23%)患者和托特罗定组有 13 例(34%)患者报告治疗无反应,差异也无统计学意义。
对于去氨加压素抵抗的患者,添加抗胆碱能药物可使超过一半的患者产生显著反应。然而,在治疗去氨加压素抵抗性遗尿症时,使用奥昔布宁或托特罗定均未观察到获益。